Gene therapy for Diabetic Neuropathy
Scientists at The University of Manchester, working with colleagues at American biotech firm Sangamo BioSciences Inc, have discovered a way of stimulating genes that prevent nerve damage caused by the diabetic neuropathy.
“Diabetic neuropathy is a major problem in insulin-dependent diabetes, particularly in patients who have had the disease for a period of time,” said Professor Tomlinson, who is based in the University’s Faculty of Life Sciences.
“This approach to gene therapy is quite different to previous attempts at treatment as we do not inject a gene that produces a ‘foreign’ copy of a therapeutic protein. This is the normal approach and has problems from immunological side-effects.
“Instead, we turn on the patient’s own gene to produce a natural version of this therapeutically beneficial protein. The most significant advantage of this is that the protein is made as if the patient’s body had made it naturally.
“Our study has shown that a single treatment with a DNA-binding protein protected against nerve damage that in humans can lead to limb loss.”
The results of the pre-clinical studies were recently presented to the American Diabetes Association in California and the first phase of clinical trials has now begun.
An estimated 50 per cent of patients with long-term diabetes develop some form of neuropathy that can cause numbness and sometimes pain and weakness in the hands, arms, feet and legs.
Currently, patients are treated with painkillers and antidepressants that do not treat the underlying nerve damage. Progression to amputation is not inevitable but is always a threat.
Reference - Medical News Today
Powered by MightyAdsense
